Financial Analysis: Civitas Solutions (CIVI) & Omnicare (OCR)
Civitas Solutions (NYSE: CIVI) and Omnicare (NYSE:OCR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.
This table compares Civitas Solutions and Omnicare’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
93.5% of Civitas Solutions shares are held by institutional investors. 5.3% of Civitas Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Civitas Solutions and Omnicare, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Civitas Solutions presently has a consensus target price of $25.50, indicating a potential upside of 31.44%. Given Civitas Solutions’ higher probable upside, equities analysts plainly believe Civitas Solutions is more favorable than Omnicare.
Valuation and Earnings
This table compares Civitas Solutions and Omnicare’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Civitas Solutions||$1.41 billion||0.51||$9.18 million||$0.53||36.60|
Civitas Solutions has higher revenue and earnings than Omnicare. Civitas Solutions is trading at a lower price-to-earnings ratio than Omnicare, indicating that it is currently the more affordable of the two stocks.
Civitas Solutions beats Omnicare on 7 of the 9 factors compared between the two stocks.
Civitas Solutions Company Profile
Civitas Solutions, Inc. is a provider of home- and community-based health and human services to individuals with intellectual, developmental, physical or behavioral disabilities and other special needs. The Company operates through two segments: Human Services and Post-Acute Specialty Rehabilitation Services (SRS). The Human Services segment provides home- and community-based human services to individuals with intellectual and/or developmental disabilities (I/DD), youth with emotional, behavioral and/or medically complex challenges or at-risk youth (ARY), and elders. The SRS segment delivers healthcare and community-based health and human services to individuals having suffered acquired brain injury, spinal injuries, and other catastrophic injuries and illnesses. Within its SRS segment, its NeuroRestorative business unit is focused on rehabilitation and transitional living services, and its CareMeridian business unit is focused on the medically-intensive post-acute care services.
Omnicare Company Profile
Omnicare, Inc. is a healthcare services company that specializes in the management of complex pharmaceutical care. The Company operates two primary businesses, Long-Term Care Group (LTC) and Specialty Care Group (SCG), each serving different customer populations. Through LTC, the Company is a provider of pharmaceuticals and related pharmacy and ancillary services to long-term care facilities, as well as chronic care facilities and other settings. As of December 31, 2014, LTC provided pharmacy services in the United States in 47 states and the District of Columbia. The Specialty Care Group (SCG) operates across a spectrum of the healthcare continuum, serving the needs of biopharmaceutical manufacturers, physicians, nurses, caregivers and patients. Its SCG services are primarily focused on the specialty pharmaceutical market and incorporate four platforms: brand support services, supply chain solutions, patient support services and specialty pharmacy.
Receive News & Ratings for Civitas Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Civitas Solutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.